CYP19A1 and polycystic ovary syndrome: We used 2 μg/mL of bacterial lipopolysaccharide (LPS) as a positive control for its ability to create a pro‐inflammatory and oxidative environment, and to reduce aromatase expression and activity, resembling PCOS conditions [26, 27, 28].